非小细胞肺癌表皮生长因子受体靶向治疗中的自噬调控研究进展

Research advances in autophagy regulation of EGFR targeted therapy for non-small cell lung cancer

近年来,以表皮生长因子受体(epidermal growth factor receptor,EGFR)为靶点的靶向治疗在非小细胞肺癌的治疗中发挥了重要作用,但原发性和继发性耐药限制了其疗效。研究表明,细胞自噬是靶向治疗耐药的机制之一,自噬调节剂的联合使用为解决非小细胞肺癌靶向治疗耐药问题带来了新的希望。

In recent years, targeted therapy with epidermal growth factor receptor（EGFR） has played an important role in the treatment of non-small cell lung cancer（NSCLC）. However, primary and acquired drug resistance have limited its efficacy. Studies have shown that autophagy is one of the mechanisms of targeted drug resistance, and the combination of autophagy regulators is expected to solve the problem of drug resistance to targeted therapy for non-small cell lung cancer.